Medicis Stock Hits New 52-Week High (MRX)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Medicis Pharmaceuticals Corporation (NYSE: MRX) hit a new 52-week high Wednesday as it is currently trading at $43.73, above its previous 52-week high of $43.70 with 2.3 million shares traded as of 1:50 p.m. ET. Average volume has been 1.8 million shares over the past 30 days.

Medicis has a market cap of $2.53 billion and is part of the health care sector and drugs industry. Shares are up 30.2% year to date as of the close of trading on Tuesday.

Medicis Pharmaceutical Corporation, a specialty pharmaceutical company, engages in the development and marketing of various products for the treatment of dermatological and aesthetic conditions in the United States and Canada. The company has a P/E ratio of 61.8, above the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Medicis as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Medicis Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.
null

If you liked this article you might like

Apple Turns 40 With Little Fanfare as March to Dow 20K Resumes: ICYMI

Medicis Pharmaceuticals Corporation (MRX): Today's Featured Drugs Laggard

Medicis Stock To Go Ex-dividend Tomorrow (MRX)

Cramer's 'Mad Money' Recap: The Worse It Gets, the Better